Drug Treatment of Obesity

被引：66

作者：

Bray G.A. ^{[1
]}

机构：

[1] Boyd Department, Pennington Biomed. Research Center, Louisiana State University, Baton Rouge, LA 70808

来源：

Reviews in Endocrine and Metabolic Disorders | 2001年 / 2卷 / 4期

关键词：

Ephedrine; Leptin; Monoamine; Orlistat; Peptides; Sibutramine; Thermogenic;

D O I：

10.1023/A:1011808701117

中图分类号：

学科分类号：

摘要：

At present only two drugs are approved for long-term treatment of obesity. Sibutramine inhibits the reuptake of serotonin and norepinephrine. In clinical trials it produces a dose-dependent 5-10% decrease in body weight. Its side effects include dry mouth, insomnia, asthenia, and constipation. In addition, sibutramine produces a small increase in blood pressure and pulse that is a contra-indication to the use of this drug in some individuals with heart disease. Xenical is the other drug approved for long-term use in the treatment of obesity. It works by blocking lipase and thus increasing the fecal loss of triglyceride. One valuable consequence of this mechanism of action is the reduction of serum cholesterol that averages about 5% more than can be accounted for by weight loss alone. In clinical trials it produces a 5-10% loss of weight. Its side effects are entirely due to undigested fat in the intestine that can lead to increased frequency and change in the character of stools. It can also lower fat-soluble vitamins. The ingestion of a vitamin supplement before bedtime is a reasonable treatment strategy. The effect on weight loss during long-term trials with these two drugs is shown in Figs 7 and 8 above. Also in this figure is data on phentermine used in trials of six months or more. Although there were differences in mean weight losses with these drugs, when the placebo effect was taken into account they all had a surprisingly similar magnitude of weight loss.

引用

页码：403 / 418

页数：15

共 77 条

[51]

Lustig R.H., Rose S.R., Burghen G.A., Velasquez-Mieyer P., Broome D.C., Smith K., Li H., Hudson M.M., Heideman R.L., Kun L.E., Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist, J Pediatr, 135, 1-2 PART, pp. 162-168, (1999)

[52]

Hauptmann J.B., Jeunet F.S., Hartmann D., Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin), Am J Clin Nutr, 5, (1992)

[53]

Drent M.L., Larsson I., William-Olsson T., Quadde F., Czubayko F., Von Bergmann K., Strobel W., Sjostrom L., Van Der Veen E.A., Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study, Int J Obes, 19, pp. 221-226, (1995)

[54]

James W.P.T., Avenell A., Broom J., Whitehead J., A One-year Trial to Assess the Value of Orlistat in the Management of Obesity, 21, 3, (1997)

[55]

Van Gaal L.F., Broom J.I., Enzi G., Toplak H., Efficacy and tolerability of orlistat in the treatment of obesity - A 6-month dose-ranging study, Eur J Clin Pharm, 54, pp. 125-132, (1998)

[56]

Sjostrom L., Rissanen A., Andersen T., Et al., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group, Lancet, 352, pp. 167-172, (1998)

[57]

Davidson M.H., Hauptman J., DiGirolamo M., Foreyt J.P., Ch H., Heber D., Heimburger D.C., Lucas C.P., Robbins D.C., Chung J., Heymsfield S.B., Long-term weight control and risk factor reduction in obese subjects treated with orlistat, a lipase inhibitor, JAMA, 281, pp. 235-242, (1999)

[58]

Finer N., James W.P., Kopelman P.G., Lean M.E., Williams G., One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor, Int J Obes Relat Metab Disord, 24, pp. 306-313, (2000)

[59]

Rossner S., Sjostrom L., Noack R., Meinders A.E., Noseda G., Weight loss, weight maintenance, and improved cardiovascular riskfactors after 2 years treatment with orlistat for obesity, Obes Res, 8, pp. 49-61, (2000)

[60]

Hauptmann J., Lucas C., Boldrin M.N., Collins H., Segal K.R., Orlistat in the long-term treatment of obesity in primary care settings, Arch Fam Med, 9, pp. 160-167, (2000)

← 1 2 3 4 5 6 7 8 →